Cargando…

Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes

Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular e...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrovic, Nenad, Todorovic, Dusan, Sarenac Vulovic, Tatjana, Sreckovic, Suncica, Zivic, Fatima, Risimic, Dijana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220700/
https://www.ncbi.nlm.nih.gov/pubmed/37241214
http://dx.doi.org/10.3390/medicina59050982
_version_ 1785049280399015936
author Petrovic, Nenad
Todorovic, Dusan
Sarenac Vulovic, Tatjana
Sreckovic, Suncica
Zivic, Fatima
Risimic, Dijana
author_facet Petrovic, Nenad
Todorovic, Dusan
Sarenac Vulovic, Tatjana
Sreckovic, Suncica
Zivic, Fatima
Risimic, Dijana
author_sort Petrovic, Nenad
collection PubMed
description Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular endothelial growth factor therapy could improve therapeutic outcomes for pseudophakic eyes with persistent diabetic macular edema. Materials and Methods: twenty-four pseudophakic eyes with refractory diabetic macular edema, that had appeared despite three previously administered intravitreal injections of aflibercept, were divided into two groups (twelve eyes in each group). The first group continued to have aflibercept administered according to a fixed dosing regimen (once in two months). Triamcinolone acetonide 10 mg/0.1 mL (administered once per four months) was included for the second group, i.e., their treatment continued with a combination of aflibercept + triamcinolone acetonide. Results: The reduction in central macular thickness was higher in the eyes treated with combined therapy (aflibercept + triamcinolone acetonide) compared with the use of aflibercept alone during the entire 12-month follow-up period (3rd month p = 0.019; 6th month p = 0.023; 9th month p = 0.027; 12th month p = 0.031). As was evident from the p-values, the differences were statistically significant. No statistically significant difference was recorded for visual acuity: 3rd month p = 0.423; 6th month p = 0.392; 9th month p = 0.413; 12th month p = 0.418. Conclusions: Combined anti-vascular endothelial growth factor and steroid therapy leads to a better anatomical outcome of persistent diabetic macular edema in pseudophakic eyes, but does not lead to a more significant improvement in visual acuity than continuous anti-VEGF therapy alone.
format Online
Article
Text
id pubmed-10220700
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102207002023-05-28 Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes Petrovic, Nenad Todorovic, Dusan Sarenac Vulovic, Tatjana Sreckovic, Suncica Zivic, Fatima Risimic, Dijana Medicina (Kaunas) Article Background and Objectives: The main cause of the vision loss in diabetics is the development of diabetic macular edema, regardless of the stage of diabetic retinopathy. The paper aimed to examine whether the additional intravitreal application of triamcinolone acetonide to continuous anti-vascular endothelial growth factor therapy could improve therapeutic outcomes for pseudophakic eyes with persistent diabetic macular edema. Materials and Methods: twenty-four pseudophakic eyes with refractory diabetic macular edema, that had appeared despite three previously administered intravitreal injections of aflibercept, were divided into two groups (twelve eyes in each group). The first group continued to have aflibercept administered according to a fixed dosing regimen (once in two months). Triamcinolone acetonide 10 mg/0.1 mL (administered once per four months) was included for the second group, i.e., their treatment continued with a combination of aflibercept + triamcinolone acetonide. Results: The reduction in central macular thickness was higher in the eyes treated with combined therapy (aflibercept + triamcinolone acetonide) compared with the use of aflibercept alone during the entire 12-month follow-up period (3rd month p = 0.019; 6th month p = 0.023; 9th month p = 0.027; 12th month p = 0.031). As was evident from the p-values, the differences were statistically significant. No statistically significant difference was recorded for visual acuity: 3rd month p = 0.423; 6th month p = 0.392; 9th month p = 0.413; 12th month p = 0.418. Conclusions: Combined anti-vascular endothelial growth factor and steroid therapy leads to a better anatomical outcome of persistent diabetic macular edema in pseudophakic eyes, but does not lead to a more significant improvement in visual acuity than continuous anti-VEGF therapy alone. MDPI 2023-05-19 /pmc/articles/PMC10220700/ /pubmed/37241214 http://dx.doi.org/10.3390/medicina59050982 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Petrovic, Nenad
Todorovic, Dusan
Sarenac Vulovic, Tatjana
Sreckovic, Suncica
Zivic, Fatima
Risimic, Dijana
Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title_full Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title_fullStr Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title_full_unstemmed Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title_short Combined Treatment of Persistent Diabetic Macular Edema with Aflibercept and Triamcinolone Acetonide in Pseudophakic Eyes
title_sort combined treatment of persistent diabetic macular edema with aflibercept and triamcinolone acetonide in pseudophakic eyes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220700/
https://www.ncbi.nlm.nih.gov/pubmed/37241214
http://dx.doi.org/10.3390/medicina59050982
work_keys_str_mv AT petrovicnenad combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes
AT todorovicdusan combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes
AT sarenacvulovictatjana combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes
AT sreckovicsuncica combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes
AT zivicfatima combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes
AT risimicdijana combinedtreatmentofpersistentdiabeticmacularedemawithafliberceptandtriamcinoloneacetonideinpseudophakiceyes